Jan 11, 2024

ALKALOID Commissions New Investment Project Worth €3.8 Million

Between 2017 and 2023, Alkaloid AD Skopje has put into operation pharmaceutical facilities spanning 10,720 m2 and invested €18.6 million at the Avtokomanda site

The commitment to following global trends in pharmacy and in the production of affordable, high-quality, effective, and safe medicines, with the Alkaloid trademark serving as a symbol of quality and safety, is firmly established in the company's corporate policy. Since 2017, Alkaloid has commenced the operation of several new pharmaceutical facilities, in line with the present capital investment plan (CAPEX 2017–2037). These facilities include a production plant dedicated to manufacturing semi-solid pharmaceutical forms, such as ointments, creams, and gels, a plant for packaging medicines, an area for weighing raw materials, and a warehouse for storing raw materials.

In the Pharmaceuticals profit center, another successfully implemented investment endeavor was commissioned in the presence of management representatives. This is a new building that offers a centralized solution for employee preparation and navigation within the Pharmaceuticals Manufacturing plants, featuring over 900 wardrobe spaces intended for employees. The complexity of this investment phase stems from the need for functional integration with all production units on the premises - manufacturing and packaging of solid, semi-solid and liquid pharmaceutical forms - where different approaches are practiced in the processes, providing even better working conditions for the employees and their safety. The new building covers a total area of 4,100 square meters, with an investment of €3.8 million for construction and equipment. Apart from service rooms, this building will incorporate exhibition displays showcasing the company's 88-year history.

With this project, Alkaloid concluded the initial quarter of its 20-year investment plan, commissioning 10,720 m2 of pharmaceutical facilities and having invested €18.6 million.

Aiming to diversify and substantially enhance production capacities for solid pharmaceutical forms, Alkaloid intends to soon finalize another new major investment venture - "Tablet Department 2.0".